Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Cancer Medicine|March 6, 2021
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumorsChristine Chevreau, Christophe Massard, Aude Flechon, et al.
Clinical Pharmacology and Therapeutics|October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
British Journal of Cancer|January 20, 2026
Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuillard, Anne Jouinot, et al.
British Journal of Cancer|January 25, 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuilard, Anne Jouinot, et al.
Bulletin Du Cancer|March 1, 2018
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|March 18, 2024
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM CohortAnna M Mc Laughlin, Thomas Helland, Fenja Klima, et al.
Fundamental & Clinical Pharmacology|January 6, 2026
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in PharmacogeneticsNicolas Picard, Estelle Ayme-Dietrich, Sylvie Quaranta, et al.
Plos One|May 9, 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabineMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, et al.
Nature Communications|December 5, 2017
Dendrogenin A drives LXR to trigger lethal autophagy in cancersGregory Segala, Marion David, Philippe de Medina, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Cancer Medicine|March 6, 2021
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumorsChristine Chevreau, Christophe Massard, Aude Flechon, et al.
Clinical Pharmacology and Therapeutics|October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
British Journal of Cancer|January 20, 2026
Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuillard, Anne Jouinot, et al.
British Journal of Cancer|January 25, 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuilard, Anne Jouinot, et al.
Bulletin Du Cancer|March 1, 2018
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|March 18, 2024
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM CohortAnna M Mc Laughlin, Thomas Helland, Fenja Klima, et al.
Fundamental & Clinical Pharmacology|January 6, 2026
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in PharmacogeneticsNicolas Picard, Estelle Ayme-Dietrich, Sylvie Quaranta, et al.
Plos One|May 9, 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabineMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, et al.
Nature Communications|December 5, 2017
Dendrogenin A drives LXR to trigger lethal autophagy in cancersGregory Segala, Marion David, Philippe de Medina, et al.
Pageof 9